$IBIO
iBio, Inc.

2024 Q4 Form 10-Q Financial Statement

#000142072024000054 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $50.00K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin -$2.750M
YoY Change -154.05%
% of Gross Profit
Research & Development $1.305M $1.606M
YoY Change -18.74% -36.97%
% of Gross Profit
Depreciation & Amortization $120.0K $165.0K
YoY Change -27.27% -39.11%
% of Gross Profit
Operating Expenses $4.106M $5.153M
YoY Change -20.32% -32.52%
Operating Profit -$4.106M -$5.103M
YoY Change -19.54% -33.17%
Interest Expense $26.00K
YoY Change -73.74%
% of Operating Profit
Other Income/Expense, Net $117.0K $29.00K
YoY Change 303.45% -70.71%
Pretax Income -$5.070M
YoY Change -32.73%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.989M -$5.746M
YoY Change -30.58% -68.31%
Net Earnings / Revenue -11492.0%
Basic Earnings Per Share -$0.46 -$0.24
Diluted Earnings Per Share -$0.46 -$0.24
COMMON SHARES
Basic Shares Outstanding 9.149M 8.638M 27.59M
Diluted Shares Outstanding 8.633M 23.97M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.500M
YoY Change -91.42%
Cash & Equivalents $11.04M $1.461M
Short-Term Investments
Other Short-Term Assets $21.60M
YoY Change -45.9%
Inventory $0.00
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $11.70M $23.02M
YoY Change -49.18% -63.78%
LONG-TERM ASSETS
Property, Plant & Equipment $3.511M $4.054M
YoY Change -13.39% 17.03%
Goodwill
YoY Change
Intangibles $5.363M $5.383M
YoY Change -0.37% -10.48%
Long-Term Investments
YoY Change
Other Assets $300.0K
YoY Change -95.06%
Total Long-Term Assets $12.82M $14.66M
YoY Change -12.55% -30.21%
TOTAL ASSETS
Total Short-Term Assets $11.70M $23.02M
Total Long-Term Assets $12.82M $14.66M
Total Assets $24.52M $37.68M
YoY Change -34.93% -55.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $855.0K $1.911M
YoY Change -55.26% -60.25%
Accrued Expenses $1.077M $3.391M
YoY Change -68.24% 30.67%
Deferred Revenue $400.0K
YoY Change
Short-Term Debt $12.60M
YoY Change
Long-Term Debt Due $400.0K
YoY Change -98.22%
Total Short-Term Liabilities $3.469M $20.71M
YoY Change -83.25% -35.69%
LONG-TERM LIABILITIES
Long-Term Debt $500.0K
YoY Change -13.19%
Other Long-Term Liabilities $3.300M
YoY Change -3.54%
Total Long-Term Liabilities $3.800M
YoY Change -4.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.469M $20.71M
Total Long-Term Liabilities $3.800M
Total Liabilities $6.763M $24.47M
YoY Change -72.36% -32.4%
SHAREHOLDERS EQUITY
Retained Earnings -$317.8M -$294.7M
YoY Change 7.86% 21.74%
Common Stock $335.6M $307.9M
YoY Change 8.99% 5.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.75M $13.21M
YoY Change
Total Liabilities & Shareholders Equity $24.52M $37.68M
YoY Change -34.93% -55.44%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.989M -$5.746M
YoY Change -30.58% -68.31%
Depreciation, Depletion And Amortization $120.0K $165.0K
YoY Change -27.27% -39.11%
Cash From Operating Activities -$3.700M -$5.340M
YoY Change -30.71% -61.75%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $50.00K
YoY Change -98.44%
Cash From Investing Activities $713.0K $50.00K
YoY Change 1326.0% 72.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -162.0K 2.472M
YoY Change -106.55% 116.65%
NET CHANGE
Cash From Operating Activities -3.700M -5.340M
Cash From Investing Activities 713.0K 50.00K
Cash From Financing Activities -162.0K 2.472M
Net Change In Cash -3.164M -2.818M
YoY Change 12.28% -77.97%
FREE CASH FLOW
Cash From Operating Activities -$3.700M -$5.340M
Capital Expenditures $0.00
Free Cash Flow -$5.340M
YoY Change -67.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8633000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1198000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8633000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1198000
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001420720
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8623676
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8637895
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.46
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.24
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.00
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.56
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.80
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2024 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.46
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.24
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.00
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.56
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.80
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
001-35023
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
iBio, Inc.
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2797813
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
11750 Sorrento Valley Road
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2024Q3 dei City Area Code
CityAreaCode
979
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
446-0027
CY2024Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q3 dei Trading Symbol
TradingSymbol
IBIO
CY2024Q3 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9149470
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11038000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14210000
CY2024Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
713000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
667000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
749000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
11705000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
15672000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
223000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
215000
CY2024Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
1101000
CY2024Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
1081000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
271000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
339000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2317000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2401000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3511000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3632000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5363000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5368000
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
26000
CY2024Q2 us-gaap Security Deposit
SecurityDeposit
26000
CY2024Q3 us-gaap Assets
Assets
24517000
CY2024Q2 us-gaap Assets
Assets
28734000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
855000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
358000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1077000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2028000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
279000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
299000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
449000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2024Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
182000
CY2024Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
178000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
227000
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
218000
CY2024Q2 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
123000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
400000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
200000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3469000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3840000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
53000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2572000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2688000
CY2024Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
16000
CY2024Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
63000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
706000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
766000
CY2024Q3 us-gaap Liabilities
Liabilities
6763000
CY2024Q2 us-gaap Liabilities
Liabilities
7410000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8637895
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8623676
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
9000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
9000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
335581000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
335162000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317836000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-313847000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
17754000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21324000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24517000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28734000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1305000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1606000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2801000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3547000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4106000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5153000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4106000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5103000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
57000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
26000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
174000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
55000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
117000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29000
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3989000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5074000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-672000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3989000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5746000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.46
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.24
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.56
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.80
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8633000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1198000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21324000
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
415000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3989000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17754000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15381000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2809000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
765000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5746000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13209000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-3989000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-5746000
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
415000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
765000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
68000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
68000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
85000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80000
CY2024Q3 us-gaap Depreciation
Depreciation
120000
CY2023Q3 us-gaap Depreciation
Depreciation
165000
CY2023Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
50000
CY2024Q3 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
19000
CY2023Q3 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
22000
CY2023Q3 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
90000
CY2024Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
41000
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-212000
CY2024Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
497000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
62000
CY2024Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-952000
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-874000
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-104000
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-95000
CY2024Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
200000
CY2023Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3715000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5340000
CY2024Q3 us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
713000
CY2023Q3 us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
0
CY2023Q3 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
50000
CY2024Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
713000
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50000
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2808000
CY2023Q3 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
204000
CY2024Q3 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
43000
CY2023Q3 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
38000
CY2024Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
51000
CY2023Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2023Q3 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
436000
CY2024Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
72000
CY2023Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
66000
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-162000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2472000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3164000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2818000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14425000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7579000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11261000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4761000
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
57000
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
200000
CY2024Q3 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.   Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (also referred to as "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (AI) and Machine Learning (ML) for the development of hard-to-drug precision antibodies. The Company’s proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since September 2022, iBio has focused on utilizing AI and ML to discover and design antibodies against hard-to-drug targets upon the acquisition of substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc") was consummated. This acquisition commenced the Company’s transition from a Contract Development and Manufacturing Organization (CDMO) to an AI-enabled biotech company.  iBio’s transition concluded in May 2024 upon the closing of the sale of the CDMO facility in Texas.  These strategic decisions the Company executed enable it to solely focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of iBio’s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile.  Another integral part of iBio’s technology stack is the ML based antibody-optimizing StableHu™ technology. When coupled with the Company’s mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio also developed the EngageTx™ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of the Company’s antibody products. By incorporating EngageTx into iBio’s own development initiatives, the Company’s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to its potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio’s technology stack also includes ShieldTx™, an antibody masking technology enabling the creation of conditionally activated antibodies. These masks keep antibodies inactive until they reach diseased tissue, where the masks are removed, and the antibodies are activated. This mechanism is thought to broaden the therapeutic window, potentially improving efficacy and safety of treatments. Conditionally activated antibodies are also believed to enable the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets which, due to their expression in multiple tissues, would otherwise raise safety concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">iBio’s scientific team, comprised of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in its San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to efficiently create a preclinical portfolio and rapidly advance preclinical pipeline programs towards clinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Artificial Intelligence in Antibody Discovery and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company’s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Clinical Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">iBio is currently in the process of building and advancing its preclinical pipeline by leveraging its technology stack focused on hard-to-drug targets and molecules offering differentiation in both obesity and cardiometabolic disease space, as well as immune-oncology. The Company’s current therapeutics being developed are all in preclinical development and it has not completed any clinical trials in humans for any therapeutic protein product candidate produced using iBio technology and there is a risk that the Company will be unsuccessful in developing or commercializing any product candidates. As the Company continues to leverage its technology stack and develop its existing immune-oncology pre-clinical pipeline, the Company also is seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. iBio also continues to assess its options rights to license three of the four assets under the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">AstralBio collaboration to add obesity and cardiometabolic programs into its pre-clinical pipeline. Under this strategic collaboration with AstraBio, it affords iBio the opportunity to expand the Company’s pipeline and build a presence in the cardiometabolic disease space.<img alt="Graphic" src="ibio-20240930x10q001.jpg" style="display:inline-block;height:232.3pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:533.25pt;"/></p>
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3700000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
11700000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11000000.0
CY2024Q3 ibio Net Loss From Continuing Operations
NetLossFromContinuingOperations
-3900000
CY2024Q3 ibio Net Loss From Operations
NetLossFromOperations
-3700000
CY2023Q3 ibio Net Loss From Operations
NetLossFromOperations
-5300000
CY2023Q4 ibio Number Of Shares Tendered In Reverse Stock Split
NumberOfSharesTenderedInReverseStockSplit
20
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued related to the extinguishment of the Term Loan and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p>
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2024Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50000
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
400000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
200000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2024Q3 ibio Percentage Of Collateral Required
PercentageOfCollateralRequired
0.05
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
200000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
200000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11038000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14210000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11261000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14425000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At September 30, 2024 and June 30, 2024, amounts in excess of insured limits were approximately $496,000 and $664,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September 30, 2024, the Company reported no <span style="-sec-ix-hidden:Hidden_uL7RTlY9I0KsEjEybP4jXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue</span></span> from continuing operations and discontinued operations. During the three months ended September 30, 2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company operates as one reportable segment, which is that of a preclinical stage biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies. In accordance with Accounting Standards Codification (“ASC”) 280, <i style="font-style:italic;">Segment Reporting</i> (“Segment Reporting”), the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under Segment Reporting due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by Segment Reporting can be found in the accompanying consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
496000
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
664000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4643000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4643000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1132000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1011000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3511000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3632000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
360000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
365000
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
5003000
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
5003000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5363000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5368000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
271000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
339000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
279000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
299000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
53000
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y11M1D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M1D
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0950
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0950
CY2024Q3 ibio Finance Lease Payments Principal
FinanceLeasePaymentsPrincipal
279000
CY2024Q3 ibio Finance Lease Payments Interest
FinanceLeasePaymentsInterest
14000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
293000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
279000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
141000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
141000
CY2024Q3 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
160000
CY2023Q3 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
155000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
653000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
674000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
693000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
715000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
736000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
189000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3660000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3989000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5074000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-672000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3989000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5746000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8633000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1198000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.46
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.24
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.56
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.80
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13102000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
338000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
415000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
762000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001420720-24-000054-index-headers.html Edgar Link pending
0001420720-24-000054-index.html Edgar Link pending
0001420720-24-000054.txt Edgar Link pending
0001420720-24-000054-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ibio-20240930.xsd Edgar Link pending
ibio-20240930x10q.htm Edgar Link pending
ibio-20240930x10q001.jpg Edgar Link pending
ibio-20240930x10q002.jpg Edgar Link pending
ibio-20240930xex31d1.htm Edgar Link pending
ibio-20240930xex31d2.htm Edgar Link pending
ibio-20240930xex32d1.htm Edgar Link pending
ibio-20240930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
ibio-20240930_cal.xml Edgar Link unprocessable
ibio-20240930_lab.xml Edgar Link unprocessable
ibio-20240930_def.xml Edgar Link unprocessable
ibio-20240930_pre.xml Edgar Link unprocessable
ibio-20240930x10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending